Comparing cancer therapy in the United States and Europe reveals striking differences in philosophy. The US system, often characterized as market-driven , tends to focus cutting-edge advancements, frequently resulting in greater costs and variable access for care. Conversely, many European systems operate under socialized medicine models, which emp